

## Report from Annual Event of BioValley Business Angels Club BioBAC and BioValley Basel Association

State Counselor Lukas Engelberger explained last week to over 110 participants how rising healthcare costs and an aging population in a budget-tight future will drive the need for affordable innovation, for instance in areas like hypertension, diabetes or Alzheimer disease. Ruben Herrendorff CEO and Co-Founder Polyneuron, a spin-off of the University Basel, showed how this company targets to selectively eliminate autoantibodies in autoimmune patients. Günter Roth CEO and Founder from BioCopy, a biotech startup from Freiburg i.B. presented a copy machine for DNA, which with a conversion into protein microarrays will allow producing a vaccine within 48 hours. Lastly Manuel Pires from Defymed, a spin-off of the Strasbourg Centre européen d'étude du Diabète, presented its novel devices, an insulin delivery device and a bioartificial pancreas. After the company presentations, the participants enjoyed a networking apéro at the Café Spitz.



Matthias Staehelin, Lukas Engelberger, Manuel Pires, Günther Roth, Ruben Herrendorff (from left to right)